Finance

Lists
IOVA:NASDAQ
Iovance Biotherapeutics Inc
$7.76
+1.70%
(+0.13) 1D
$7.72
-0.52% (-0.040)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IOVA...
Open
$7.80
High
$7.92
Low
$7.46
Mkt. cap
3.59B
Avg. vol.
14.69M
Volume
11.68M
52-wk high
$15.37
52-wk low
$2.08
EPS
-$0.52
Beta
0.88
Shares outstanding
462.66M
No. of employees
975
Open
$7.80
High
$7.92
Low
$7.46
Mkt. cap
3.59B
Avg. vol.
14.69M
Volume
11.68M
52-wk high
$15.37
52-wk low
$2.08
EPS
-$0.52
Beta
0.88
Shares outstanding
462.66M
No. of employees
975
News stories
From web sources and news partners
Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania. The company works to develop tumor-infiltrating lymphocyte therapies against cancer. Wikipedia
About Iovance Biotherapeutics Inc
CEO-
Employees975
Founded2007
HeadquartersSan Carlos, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 10 analysts giving stock ratings to IOVA in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for IOVA in the last 3 months.
Highest
Current $7.76
$20.00 (+157.73%)
Average
$14.80 (+90.72%)
Lowest
$8.00 (+3.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$20.00
+157.7%
11/11/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$12.00
+54.6%
11/06/2026
Etzer Darout
Barclays
Buy
Maintained
$19.00
+144.8%
11/06/2026
David Dai
UBS
Hold
Reiterated
$8.00
+3.1%
11/03/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
$9.00
+16%
10/30/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$18.00
+132%
10/29/2026
Andrew Tsai
Jefferies
Buy
Maintained
$20.00
+157.7%
10/23/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
$16.00
+106.2%
09/29/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$15.00
+93.3%
09/24/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$11.00
+41.8%
08/17/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$7.00
-9.8%
08/06/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$10.00
+28.9%
06/22/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$14.00
+80.4%
05/07/2026
Asthika Goonewardene
Truist Financial
Hold
Maintained
-
-
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
86.77M
71.43M
99.31M
121.47M
Cost of goods sold
43.11M
42.50M
43.60M
48.03M
Cost of revenue
43.11M
42.50M
43.60M
48.03M
Research and development expenses
71.20M
62.49M
58.85M
49.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
36.40M
38.95M
39.27M
38.58M
Operating expense
117.12M
109.98M
107.62M
97.41M
Total operating expenses
160.23M
152.47M
151.22M
145.44M
Operating income
-73.46M
-81.04M
-51.90M
-23.97M
Other non operating income
-
-
-
-
EBT including unusual items
-71.72M
-79.71M
-48.69M
-21.66M
EBT excluding unusual items
-73.06M
-80.83M
-48.69M
-21.66M
Income tax expense
184.00K
-665.00K
-1.37M
614.00K
Effective tax rate
-0.26%
0.83%
2.82%
-2.84%
Other operating expenses
-
-
-
-
Net income
-71.90M
-79.04M
-47.32M
-22.27M
Net profit margin
-82.87%
-110.66%
-47.64%
-18.33%
Earnings per share
-0.18
-0.19
-0.11
-0.05
Interest and investment income
398.00K
213.00K
3.22M
2.31M
Interest expense
-
-
-
-
Net interest expenses
398.00K
213.00K
3.22M
2.31M
Depreciation and amortization charges
9.52M
8.54M
9.50M
9.50M
EBITDA
-63.53M
-72.50M
-42.40M
-14.47M
Gain or loss from assets sale
-
28.00K
642.00K
2.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps